Unlock the Next Generation of Metabolic Research with GLP-3R

GLP-3R represents the frontier of peptide engineering, known in the scientific community as a "GLP-3" or triple agonist. Unlike traditional mono-agonists (like Semaglutide) or dual-agonists (like Tirzepatide), GLP-3R is designed to activate three distinct receptor pathways:

1. GLP-1 (Glucagon-like Peptide-1)
2. GIP (Glucose-dependent Insulinotropic Polypeptide)
3. GCG (Glucagon)

This tri-agonist mechanism mimics the biological profile of Retatrutide, currently the subject of intense study for its potential to revolutionize obesity and Type 2 diabetes management. By engaging the glucagon receptor in addition to GLP-1 and GIP, GLP-3R is unique in its potential ability to increase energy expenditure (thermogenesis) while simultaneously regulating appetite and insulin sensitivity.